Indian Pharma Takes Hedging Hit

28 Apr 2008

Mumbai-based drugmaker Wockhardt posted an unexpected 23% fall in quarterly net profit caused by derivatives-related losses. A one-time mark-to-market charge of INR279 million were due to long-term hedging instruments bought to reduce loan interest costs. The hedging covered interest for 50% of its long-term loans.

Click here for ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Oops, something went wrong

We're sorry but at the moment we can't load this data